Clinical trials recruiting for Metastatic Prostate Adenocarcinoma
13
Recruiting trials
36
US states with sites
3
Countries
8%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 4 |
| Washington | 4 |
| Illinois | 3 |
| Michigan | 3 |
| Texas | 3 |
| Colorado | 2 |
| Delaware | 2 |
| Georgia | 2 |
| Idaho | 2 |
| Iowa | 2 |
| Minnesota | 2 |
| Missouri | 2 |
Top cities
Seattle, Washington 4Chicago, Illinois 3Ames, Iowa 2Anaconda, Montana 2Ann Arbor, Michigan 2Basking Ridge, New Jersey 2Billings, Montana 2Bismarck, North Dakota 2Boone, Iowa 2Bozeman, Montana 2
Self-screener
Recruiting trials
- Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
- Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
- Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer
- Measuring Oncological Value of Exercise and Statin
- Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
- Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
- Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
- Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Related conditions
Trials recruiting for Metastatic Prostate Adenocarcinoma often also study these conditions. Each links to its own recruiting-trial list.
Prostate cancer 1234Stage IVB Prostate Cancer AJCC v8 27Castration-Resistant Prostate Carcinoma 13Stage IVA Prostate Cancer AJCC v8 13Stage IV Prostate Cancer AJCC v8 14Metastatic Castration-Resistant Prostate Carcinoma 7Castration-Sensitive Prostate Carcinoma 3Prostate Adenocarcinoma 52Ovarian cancer 118Metastatic Renal Cell Carcinoma 8
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Metastatic Prostate Adenocarcinoma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.